Bioventus Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Rob Claypoole

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	less than a year
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	2.7yrs
Durée moyenne du mandat des membres du conseil d'administration	4.2yrs

Mises à jour récentes de la gestion

Recent updates

Bioventus Non-GAAP EPS of $0.10 misses by $0.06, revenue of $140.3M beats by $1.97M

Aug 11

Bioventus stock rises as FDA clears SonaStar Elite for use in tumor removal

Aug 03

Bioventus: Strong Value Gap, Insulated Via Leading Market Share

Jun 14

Bioventus: Thoughts After An Active First Year

Mar 29

PDG

Rob Claypoole (52 yo)

less than a year

Titularisation

Mr. Robert E. Claypoole, also known as Rob, is President, Chief Executive Officer and Director of Bioventus Inc. from January 10, 2024. He was Executive Vice President and President, US for Mlnlycke Health...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Mark Singleton	Senior VP & CFO	2.7yrs	US$1.06m	0.13% $ 968.6k
Anthony D'Adamio	Senior VP	7.3yrs	US$924.52k	0.15% $ 1.1m
Robert Claypoole	President	less than a year	pas de données	pas de données
Mike Crowe	Senior Vice President of Operations	1.1yrs	pas de données	pas de données
David Crawford	Vice President of Investor Relations & Treasurer	no data	pas de données	pas de données
Katrina Church	Senior VP & Chief Compliance Officer	4.3yrs	pas de données	0.063% $ 470.1k
Helen Leupold	Senior VP & Chief Human Resources Officer	1.6yrs	pas de données	pas de données
Larry Chen	Managing Director of China & Asia Pacific	3.7yrs	pas de données	pas de données

2.7yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Gestion expérimentée: L'équipe de direction de BVS est considérée comme expérimentée (ancienneté moyenne 2.7 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Robert Claypoole	President	less than a year	pas de données	pas de données
Guy Nohra	Independent Director	4.2yrs	US$153.23k	0.15% $ 1.1m
Johnathan Bartholdson	Independent Director	1.8yrs	US$211.70k	0.070% $ 519.8k
Martin Sutter	Independent Director	4.2yrs	US$150.73k	0.090% $ 670.3k
William Hawkins	Independent Chairman of the Board	4.2yrs	US$199.48k	0.35% $ 2.6m
Guido Neels	Independent Director	4.2yrs	US$148.23k	0.090% $ 670.3k
Susan Stalnecker	Independent Director	4.2yrs	US$165.73k	0.12% $ 906.7k
Mary Ladone	Independent Director	3.3yrs	US$158.23k	0.080% $ 598.9k
Philip Cowdy	Independent Director	4.2yrs	pas de données	0.018% $ 133.5k
Patrick Beyer	Independent Director	3.1yrs	US$150.73k	0.076% $ 569.8k
Michelle McMurry-Heath	Independent Director	2.8yrs	US$156.98k	0.074% $ 550.0k

4.2yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de BVS sont considérés comme expérimentés (ancienneté moyenne 4.2 ans).

Bioventus Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Bioventus Inc., Annual General Meeting, Jun 11, 2024

Senior VP & CFO notifies of intention to sell stock

Bioventus Inc Announces Executive Changes

Interim CEO & Director recently bought US$165k worth of stock

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Second quarter 2024 earnings released: US$0.38 loss per share (vs US$0.059 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Bioventus Inc. Revises Earnings Guidance for the Twelve Months Ending December 31, 2024

Bioventus Inc. to Report Q3, 2024 Results on Nov 05, 2024

Forecast to breakeven in 2025

New minor risk - Shareholder dilution

New minor risk - Profitability

Price target increased by 32% to US$12.33

Forecast breakeven date moved forward to 2024

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bioventus Inc. Raises Earnings Guidance for the Full Year 2024

Bioventus Inc. to Report Q2, 2024 Results on Aug 06, 2024

Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bioventus Inc. to Report Q1, 2024 Results on May 07, 2024

Bioventus Inc., Annual General Meeting, Jun 11, 2024

Senior VP & CFO notifies of intention to sell stock

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Bioventus Inc. Provides Earnings Guidance for the Year 2024

New major risk - Revenue and earnings growth

Bioventus Inc. to Report Q4, 2023 Results on Mar 12, 2024

Now 21% undervalued

Bioventus: Bullish On Path To Profitability

Bioventus Inc Announces Executive Changes

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Bioventus Inc. to Report Q3, 2023 Results on Nov 07, 2023

Interim CEO & Director recently bought US$165k worth of stock

Price target increased by 29% to US$4.50

High number of new and inexperienced directors

Bioventus Inc. to Report Q2, 2023 Results on Aug 08, 2023

LifeNet Health, Inc. completed the acquisition of Wound Business of Bioventus Inc.

LifeNet Health, Inc. completed the acquisition of Wound Business of Bioventus Inc.

Bioventus Inc. announced delayed 10-Q filing

LifeNet Health, Inc. signed a definitive agreement to acquire Wound Business of Bioventus Inc.

Bioventus Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

An unknown buyer acquired all shares in Harrow Health, Inc. from SWK Holdings Corporation (NasdaqCM:SWKH).

An unknown buyer acquired all shares in Harrow Health, Inc. from SWK Holdings Corporation (NasdaqCM:SWKH).

Kirby Mcinerney LLP Announces the Filing of a Securities Class Action on Behalf Bioventus Inc. Investors

Bioventus Inc. Appoints John A. Bartholdson to the Board as A Class II Director

Bioventus Inc. Announces Impairment of Goodwill for the Three Months Ended October 1, 2022

Bioventus Inc. announced delayed 10-Q filing

Price target decreased to US$9.20

High number of new and inexperienced directors

Price target decreased to US$9.20

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Bioventus Inc. Revises Earnings Guidance for the Twelve Months Ending December 31, 2022

Bioventus Inc. to Report Q3, 2022 Results on Nov 08, 2022

Bioventus: Reiterating Buy Thesis Following Q2 Earnings

Bioventus Inc. Announces Resignation of Stavros G. Vizirgianakis as Member of the Board of Directors

Price target decreased to US$16.40

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Bioventus Inc. Updates Earnings Guidance for the Full Year 2022

Bioventus Non-GAAP EPS of $0.10 misses by $0.06, revenue of $140.3M beats by $1.97M

Bioventus Receives FDA 510(k) Clearance for SonaStar Elite

Bioventus stock rises as FDA clears SonaStar Elite for use in tumor removal

Bioventus Inc. to Report Q2, 2022 Results on Aug 11, 2022

Bioventus Inc. (NasdaqGS:BVS) completes the acquisition of Cartiheal Ltd for $450 million.

Bioventus Inc. Announces Executive Changes

Bioventus: Strong Value Gap, Insulated Via Leading Market Share

Price target decreased to US$19.40

First quarter 2022 earnings: EPS misses analyst expectations

Bioventus Inc. Reaffirms Earnings Guidance for the Full-Year 2022

Price target increased to US$21.20